HIMS pushes into longevity and peptides with new hire, Jonah Lupton notes

HIMS pushes into longevity and peptides with new hire, Jonah Lupton notes
HIMS targets peptides growth before FDA hearing

Jonah Lupton, investor and market commentator at Social Media / FinTwit, highlights that HIMS is ramping up efforts in the longevity and peptides sector.

He points to a significant hire as a signal the company is preparing for a major move, especially with the upcoming U.S. FDA and HHS hearing on peptides in July. Lupton underscores the importance of expertise in this area and references discussions with peptide experts he has recently followed on various podcasts.

Lupton has previously commented on high-profile corporate moves, pointing to RDDT's consideration of an exclusive $1 billion data licensing deal. He also identified MRVL as a notable player with a $260 billion market cap alongside other picks including CRDO, ALAB, and RDDT in a separate note highlighting his stock selections. His recent focus on HIMS marks a continuation of tracking companies with growth potential and major sector developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.